5-[2-[(3,4-Dichlorobenzoyl)amino]ethyl]-N-hydroxy-3-isoxazolecarboxamide | 2245942-72-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-[2-[(3,4-Dichlorobenzoyl)amino]ethyl]-N-hydroxy-3-isoxazolecarboxamide
• 英文别名: 5-[2-[(3,4-dichlorobenzoyl)amino]ethyl]-N-hydroxy-1,2-oxazole-3-carboxamide
• CAS: 2245942-72-5
• 化学式: C₁₃H₁₁Cl₂N₃O₄
• 分子量: 344.15
• InChiKey: JFGOILLZIAIYGA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors
  申请人：The George Washington University, a Congressionally Chartered Not-For-Profit Corporation

  公开号：US11472780B2

  公开（公告）日：2022-10-18

  The present disclosure provides compounds represented by Formula (I): and pharmaceutically acceptable salts, solvates, e.g., hydrates, and prodrugs thereof wherein X and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat diseases and conditions, e.g., cancer, wherein inhibition of HDAC provides a benefit.

  本公开提供了由式(I)代表的化合物：及其药学上可接受的盐、溶液剂，例如水合物和原药，其中X和n如说明书中所定义。 本公开还提供了用于治疗疾病和病症（如癌症）的式（I）化合物，其中抑制 HDAC 提供了益处。
• ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS
  申请人：The George Washington University, A Congressionally Chartered Not-For-Profit Corporation

  公开号：EP3600295A1

  公开（公告）日：2020-02-05
• Isoxazole Hydroxamic Acids As Histone Deacetylase 6 Inhibitors
  申请人：The George Washington University

  公开号：US20200115350A1

  公开（公告）日：2020-04-16

  The present disclosure provides compounds represented by Formula (I): and pharmaceutically acceptable salts, solvates, e.g., hydrates, and prodrugs thereof wherein X and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat diseases and conditions, e.g., cancer, wherein inhibition of HDAC provides a benefit.
• HDAC6-ACTIVATED MACROPHAGES, COMPOSITIONS, AND USES THEREOF
  申请人：The George Washington University, A Congressionally Chartered Not-for-Profit Corporation

  公开号：US20220401474A1

  公开（公告）日：2022-12-22

  The present disclosure provides histone deacetylase 6 (HDAC6)-activated macrophages, compositions comprising HDAC6-activated macrophages, methods of making HDAC6-activated macrophages, and methods of treating diseases, e.g., cancer, by administering a therapeutically effective amount of HDAC6-activated macrophages.
• [EN] ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS<br/>[FR] ACIDES ISOXAZOLE HYDROXAMIQUES EN TANT QU'INHIBITEURS D'HISTONE DÉSACÉTYLASE 6
  申请人：UNIV GEORGE WASHINGTON

  公开号：WO2018183701A1

  公开（公告）日：2018-10-04

  The present disclosure provides compounds represented by Formula (I): (Formula(I) and pharmaceutically acceptable salts, solvates, e.g., hydrates, and prodrugs thereof, wherein X and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat diseases and conditions, e.g., cancer, wherein inhibition of HDAC provides a benefit.